Analysis of Solvency Ratios
Quarterly Data
Solvency ratios also known as long-term debt ratios measure a company’s ability to meet long-term obligations.
Solvency Ratios (Summary)
Danaher Corp., solvency ratios (quarterly data)
Based on: 10-Q (filing date: 2020-10-22), 10-Q (filing date: 2020-07-23), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-21), 10-Q (filing date: 2019-10-24), 10-Q (filing date: 2019-07-18), 10-Q (filing date: 2019-04-18), 10-K (filing date: 2019-02-21), 10-Q (filing date: 2018-10-18), 10-Q (filing date: 2018-07-19), 10-Q (filing date: 2018-04-19), 10-K (filing date: 2018-02-21), 10-Q (filing date: 2017-10-19), 10-Q (filing date: 2017-07-20), 10-Q (filing date: 2017-04-20), 10-K (filing date: 2017-02-22), 10-Q (filing date: 2016-10-20), 10-Q (filing date: 2016-07-25), 10-Q (filing date: 2016-04-21), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-10-22), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-23).
Solvency ratio | Description | The company |
---|---|---|
Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Danaher Corp.’s debt to equity ratio improved from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020. |
Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Danaher Corp.’s debt to capital ratio improved from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020. |
Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Danaher Corp.’s debt to assets ratio improved from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020. |
Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Danaher Corp.’s financial leverage ratio decreased from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020. |
Solvency ratio | Description | The company |
---|---|---|
Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Danaher Corp.’s interest coverage ratio deteriorated from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020. |
Debt to Equity
Danaher Corp., debt to equity calculation (quarterly data)
Oct 2, 2020 | Jul 3, 2020 | Apr 3, 2020 | Dec 31, 2019 | Sep 27, 2019 | Jun 28, 2019 | Mar 29, 2019 | Dec 31, 2018 | Sep 28, 2018 | Jun 29, 2018 | Mar 30, 2018 | Dec 31, 2017 | Sep 29, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jul 1, 2016 | Apr 1, 2016 | Dec 31, 2015 | Oct 2, 2015 | Jul 3, 2015 | Apr 3, 2015 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Notes payable and current portion of long-term debt | 19,700 | 17,200 | 3,234,300 | 212,400 | 1,068,600 | 153,700 | 36,600 | 51,800 | 59,800 | 175,100 | 98,700 | 194,700 | 182,200 | 169,500 | 2,221,000 | 2,594,800 | 809,100 | 2,644,500 | 197,000 | 845,200 | 3,489,300 | 110,100 | 123,700 | |||||||
Long-term debt, excluding current portion | 21,806,100 | 22,370,000 | 22,737,200 | 21,516,700 | 16,536,200 | 10,144,400 | 9,458,200 | 9,688,500 | 10,558,000 | 11,145,600 | 10,410,700 | 10,327,400 | 10,726,800 | 11,422,500 | 9,729,300 | 9,674,200 | 7,503,100 | 12,007,700 | 12,194,700 | 12,025,200 | 11,522,700 | 3,052,700 | 3,053,800 | |||||||
Total debt | 21,825,800 | 22,387,200 | 25,971,500 | 21,729,100 | 17,604,800 | 10,298,100 | 9,494,800 | 9,740,300 | 10,617,800 | 11,320,700 | 10,509,400 | 10,522,100 | 10,909,000 | 11,592,000 | 11,950,300 | 12,269,000 | 8,312,200 | 14,652,200 | 12,391,700 | 12,870,400 | 15,012,000 | 3,162,800 | 3,177,500 | |||||||
Total Danaher stockholders’ equity | 37,961,000 | 36,261,700 | 31,055,100 | 30,270,600 | 32,502,300 | 32,201,200 | 31,556,600 | 28,214,400 | 27,673,400 | 27,212,300 | 27,189,900 | 26,358,200 | 25,375,400 | 24,590,000 | 23,785,800 | 23,002,800 | 23,191,600 | 25,045,100 | 24,504,700 | 23,690,300 | 23,112,700 | 24,101,200 | 23,321,000 | |||||||
Solvency Ratio | ||||||||||||||||||||||||||||||
Debt to equity1 | 0.57 | 0.62 | 0.84 | 0.72 | 0.54 | 0.32 | 0.30 | 0.35 | 0.38 | 0.42 | 0.39 | 0.40 | 0.43 | 0.47 | 0.50 | 0.53 | 0.36 | 0.59 | 0.51 | 0.54 | 0.65 | 0.13 | 0.14 | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Debt to Equity, Competitors2 | ||||||||||||||||||||||||||||||
Becton, Dickinson & Co. | 0.78 | 1.01 | 0.92 | 0.92 | 0.94 | 0.97 | 0.98 | 1.02 | 1.04 | 1.08 | 1.07 | 1.46 | 1.51 | 1.29 | 1.45 | 1.51 | 1.48 | 1.63 | 1.77 | 1.79 | 1.82 | 1.93 | 2.00 | |||||||
Boston Scientific Corp. | 0.60 | 0.61 | 0.75 | 0.72 | 1.12 | 1.01 | 1.00 | 0.81 | 0.80 | 0.84 | 0.82 | 0.80 | 0.75 | 0.81 | 0.78 | 0.81 | 0.84 | 0.87 | 0.88 | 0.90 | 0.91 | 0.78 | 0.66 | |||||||
Edwards Lifesciences Corp. | 0.14 | 0.15 | 0.15 | 0.14 | 0.16 | 0.17 | 0.17 | 0.19 | 0.36 | 0.38 | 0.32 | 0.35 | 0.33 | 0.35 | 0.31 | 0.31 | 0.22 | 0.24 | 0.26 | 0.24 | 0.25 | 0.26 | 0.27 | |||||||
Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||
Medtronic PLC | 0.49 | 0.51 | 0.52 | 0.51 | 0.50 | 0.50 | 0.50 | 0.51 | 0.57 | 0.56 | 0.67 | 0.66 | 0.65 | 0.65 | 0.63 | 0.60 | 0.71 | 0.69 | 0.67 | 0.68 | 1.43 | 0.70 | 0.67 | |||||||
Stryker Corp. | 1.01 | 1.01 | 0.80 | 0.87 | 0.68 | 0.71 | 0.72 | 0.84 | 0.73 | 0.76 | 0.86 | 0.72 | 0.69 | 0.73 | 0.74 | 0.72 | 0.73 | 0.84 | 0.85 | 0.47 | 0.41 | 0.41 | 0.42 | |||||||
Thermo Fisher Scientific Inc. | 0.66 | 0.71 | 0.70 | 0.60 | 0.58 | 0.66 | 0.66 | 0.69 | 0.70 | 0.73 | 0.80 | 0.83 | 0.89 | 0.75 | 0.78 | 0.77 | 0.87 | 0.67 | 0.72 | 0.59 | 0.64 | 0.68 | 0.75 | |||||||
UnitedHealth Group Inc. | 0.67 | 0.72 | 0.91 | 0.71 | 0.82 | 0.80 | 0.74 | 0.71 | 0.67 | 0.73 | 0.75 | 0.66 | 0.65 | 0.74 | 0.81 | 0.86 | 0.88 | 0.91 | 0.96 | 0.95 | 0.96 | 0.55 | 0.58 |
Based on: 10-Q (filing date: 2020-10-22), 10-Q (filing date: 2020-07-23), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-21), 10-Q (filing date: 2019-10-24), 10-Q (filing date: 2019-07-18), 10-Q (filing date: 2019-04-18), 10-K (filing date: 2019-02-21), 10-Q (filing date: 2018-10-18), 10-Q (filing date: 2018-07-19), 10-Q (filing date: 2018-04-19), 10-K (filing date: 2018-02-21), 10-Q (filing date: 2017-10-19), 10-Q (filing date: 2017-07-20), 10-Q (filing date: 2017-04-20), 10-K (filing date: 2017-02-22), 10-Q (filing date: 2016-10-20), 10-Q (filing date: 2016-07-25), 10-Q (filing date: 2016-04-21), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-10-22), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-23).
1 Q3 2020 Calculation
Debt to equity = Total debt ÷ Total Danaher stockholders’ equity
= 21,825,800 ÷ 37,961,000 = 0.57
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Danaher Corp.’s debt to equity ratio improved from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020. |
Debt to Capital
Danaher Corp., debt to capital calculation (quarterly data)
Oct 2, 2020 | Jul 3, 2020 | Apr 3, 2020 | Dec 31, 2019 | Sep 27, 2019 | Jun 28, 2019 | Mar 29, 2019 | Dec 31, 2018 | Sep 28, 2018 | Jun 29, 2018 | Mar 30, 2018 | Dec 31, 2017 | Sep 29, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jul 1, 2016 | Apr 1, 2016 | Dec 31, 2015 | Oct 2, 2015 | Jul 3, 2015 | Apr 3, 2015 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Notes payable and current portion of long-term debt | 19,700 | 17,200 | 3,234,300 | 212,400 | 1,068,600 | 153,700 | 36,600 | 51,800 | 59,800 | 175,100 | 98,700 | 194,700 | 182,200 | 169,500 | 2,221,000 | 2,594,800 | 809,100 | 2,644,500 | 197,000 | 845,200 | 3,489,300 | 110,100 | 123,700 | |||||||
Long-term debt, excluding current portion | 21,806,100 | 22,370,000 | 22,737,200 | 21,516,700 | 16,536,200 | 10,144,400 | 9,458,200 | 9,688,500 | 10,558,000 | 11,145,600 | 10,410,700 | 10,327,400 | 10,726,800 | 11,422,500 | 9,729,300 | 9,674,200 | 7,503,100 | 12,007,700 | 12,194,700 | 12,025,200 | 11,522,700 | 3,052,700 | 3,053,800 | |||||||
Total debt | 21,825,800 | 22,387,200 | 25,971,500 | 21,729,100 | 17,604,800 | 10,298,100 | 9,494,800 | 9,740,300 | 10,617,800 | 11,320,700 | 10,509,400 | 10,522,100 | 10,909,000 | 11,592,000 | 11,950,300 | 12,269,000 | 8,312,200 | 14,652,200 | 12,391,700 | 12,870,400 | 15,012,000 | 3,162,800 | 3,177,500 | |||||||
Total Danaher stockholders’ equity | 37,961,000 | 36,261,700 | 31,055,100 | 30,270,600 | 32,502,300 | 32,201,200 | 31,556,600 | 28,214,400 | 27,673,400 | 27,212,300 | 27,189,900 | 26,358,200 | 25,375,400 | 24,590,000 | 23,785,800 | 23,002,800 | 23,191,600 | 25,045,100 | 24,504,700 | 23,690,300 | 23,112,700 | 24,101,200 | 23,321,000 | |||||||
Total capital | 59,786,800 | 58,648,900 | 57,026,600 | 51,999,700 | 50,107,100 | 42,499,300 | 41,051,400 | 37,954,700 | 38,291,200 | 38,533,000 | 37,699,300 | 36,880,300 | 36,284,400 | 36,182,000 | 35,736,100 | 35,271,800 | 31,503,800 | 39,697,300 | 36,896,400 | 36,560,700 | 38,124,700 | 27,264,000 | 26,498,500 | |||||||
Solvency Ratio | ||||||||||||||||||||||||||||||
Debt to capital1 | 0.37 | 0.38 | 0.46 | 0.42 | 0.35 | 0.24 | 0.23 | 0.26 | 0.28 | 0.29 | 0.28 | 0.29 | 0.30 | 0.32 | 0.33 | 0.35 | 0.26 | 0.37 | 0.34 | 0.35 | 0.39 | 0.12 | 0.12 | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Debt to Capital, Competitors2 | ||||||||||||||||||||||||||||||
Becton, Dickinson & Co. | 0.44 | 0.50 | 0.48 | 0.48 | 0.48 | 0.49 | 0.50 | 0.51 | 0.51 | 0.52 | 0.52 | 0.59 | 0.60 | 0.56 | 0.59 | 0.60 | 0.60 | 0.62 | 0.64 | 0.64 | 0.64 | 0.66 | 0.67 | |||||||
Boston Scientific Corp. | 0.37 | 0.38 | 0.43 | 0.42 | 0.53 | 0.50 | 0.50 | 0.45 | 0.44 | 0.46 | 0.45 | 0.44 | 0.43 | 0.45 | 0.44 | 0.45 | 0.46 | 0.47 | 0.47 | 0.47 | 0.48 | 0.44 | 0.40 | |||||||
Edwards Lifesciences Corp. | 0.12 | 0.13 | 0.13 | 0.13 | 0.13 | 0.15 | 0.15 | 0.16 | 0.26 | 0.27 | 0.25 | 0.26 | 0.25 | 0.26 | 0.24 | 0.24 | 0.18 | 0.20 | 0.21 | 0.19 | 0.20 | 0.21 | 0.21 | |||||||
Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||
Medtronic PLC | 0.33 | 0.34 | 0.34 | 0.34 | 0.33 | 0.34 | 0.33 | 0.34 | 0.36 | 0.36 | 0.40 | 0.40 | 0.39 | 0.39 | 0.39 | 0.38 | 0.41 | 0.41 | 0.40 | 0.40 | 0.59 | 0.41 | 0.40 | |||||||
Stryker Corp. | 0.50 | 0.50 | 0.44 | 0.46 | 0.41 | 0.42 | 0.42 | 0.46 | 0.42 | 0.43 | 0.46 | 0.42 | 0.41 | 0.42 | 0.43 | 0.42 | 0.42 | 0.46 | 0.46 | 0.32 | 0.29 | 0.29 | 0.30 | |||||||
Thermo Fisher Scientific Inc. | 0.40 | 0.42 | 0.41 | 0.37 | 0.37 | 0.40 | 0.40 | 0.41 | 0.41 | 0.42 | 0.44 | 0.45 | 0.47 | 0.43 | 0.44 | 0.44 | 0.47 | 0.40 | 0.42 | 0.37 | 0.39 | 0.40 | 0.43 | |||||||
UnitedHealth Group Inc. | 0.40 | 0.42 | 0.48 | 0.41 | 0.45 | 0.44 | 0.43 | 0.41 | 0.40 | 0.42 | 0.43 | 0.40 | 0.39 | 0.43 | 0.45 | 0.46 | 0.47 | 0.48 | 0.49 | 0.49 | 0.49 | 0.35 | 0.37 |
Based on: 10-Q (filing date: 2020-10-22), 10-Q (filing date: 2020-07-23), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-21), 10-Q (filing date: 2019-10-24), 10-Q (filing date: 2019-07-18), 10-Q (filing date: 2019-04-18), 10-K (filing date: 2019-02-21), 10-Q (filing date: 2018-10-18), 10-Q (filing date: 2018-07-19), 10-Q (filing date: 2018-04-19), 10-K (filing date: 2018-02-21), 10-Q (filing date: 2017-10-19), 10-Q (filing date: 2017-07-20), 10-Q (filing date: 2017-04-20), 10-K (filing date: 2017-02-22), 10-Q (filing date: 2016-10-20), 10-Q (filing date: 2016-07-25), 10-Q (filing date: 2016-04-21), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-10-22), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-23).
1 Q3 2020 Calculation
Debt to capital = Total debt ÷ Total capital
= 21,825,800 ÷ 59,786,800 = 0.37
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Danaher Corp.’s debt to capital ratio improved from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020. |
Debt to Assets
Danaher Corp., debt to assets calculation (quarterly data)
Oct 2, 2020 | Jul 3, 2020 | Apr 3, 2020 | Dec 31, 2019 | Sep 27, 2019 | Jun 28, 2019 | Mar 29, 2019 | Dec 31, 2018 | Sep 28, 2018 | Jun 29, 2018 | Mar 30, 2018 | Dec 31, 2017 | Sep 29, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jul 1, 2016 | Apr 1, 2016 | Dec 31, 2015 | Oct 2, 2015 | Jul 3, 2015 | Apr 3, 2015 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Notes payable and current portion of long-term debt | 19,700 | 17,200 | 3,234,300 | 212,400 | 1,068,600 | 153,700 | 36,600 | 51,800 | 59,800 | 175,100 | 98,700 | 194,700 | 182,200 | 169,500 | 2,221,000 | 2,594,800 | 809,100 | 2,644,500 | 197,000 | 845,200 | 3,489,300 | 110,100 | 123,700 | |||||||
Long-term debt, excluding current portion | 21,806,100 | 22,370,000 | 22,737,200 | 21,516,700 | 16,536,200 | 10,144,400 | 9,458,200 | 9,688,500 | 10,558,000 | 11,145,600 | 10,410,700 | 10,327,400 | 10,726,800 | 11,422,500 | 9,729,300 | 9,674,200 | 7,503,100 | 12,007,700 | 12,194,700 | 12,025,200 | 11,522,700 | 3,052,700 | 3,053,800 | |||||||
Total debt | 21,825,800 | 22,387,200 | 25,971,500 | 21,729,100 | 17,604,800 | 10,298,100 | 9,494,800 | 9,740,300 | 10,617,800 | 11,320,700 | 10,509,400 | 10,522,100 | 10,909,000 | 11,592,000 | 11,950,300 | 12,269,000 | 8,312,200 | 14,652,200 | 12,391,700 | 12,870,400 | 15,012,000 | 3,162,800 | 3,177,500 | |||||||
Total assets | 72,890,700 | 71,268,400 | 68,930,300 | 62,081,600 | 61,531,100 | 53,322,000 | 51,774,400 | 47,832,500 | 47,719,500 | 48,055,800 | 47,145,200 | 46,648,600 | 45,851,300 | 45,646,800 | 45,245,100 | 45,295,300 | 41,297,500 | 51,503,700 | 48,385,600 | 48,222,200 | 49,707,900 | 36,986,800 | 36,072,300 | |||||||
Solvency Ratio | ||||||||||||||||||||||||||||||
Debt to assets1 | 0.30 | 0.31 | 0.38 | 0.35 | 0.29 | 0.19 | 0.18 | 0.20 | 0.22 | 0.24 | 0.22 | 0.23 | 0.24 | 0.25 | 0.26 | 0.27 | 0.20 | 0.28 | 0.26 | 0.27 | 0.30 | 0.09 | 0.09 | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Debt to Assets, Competitors2 | ||||||||||||||||||||||||||||||
Becton, Dickinson & Co. | 0.35 | 0.40 | 0.37 | 0.37 | 0.39 | 0.39 | 0.40 | 0.40 | 0.41 | 0.42 | 0.41 | 0.50 | 0.51 | 0.43 | 0.45 | 0.45 | 0.46 | 0.48 | 0.49 | 0.48 | 0.49 | 0.49 | 0.55 | |||||||
Boston Scientific Corp. | 0.30 | 0.31 | 0.34 | 0.33 | 0.41 | 0.39 | 0.39 | 0.34 | 0.33 | 0.33 | 0.30 | 0.29 | 0.30 | 0.32 | 0.31 | 0.30 | 0.31 | 0.30 | 0.32 | 0.31 | 0.32 | 0.30 | 0.26 | |||||||
Edwards Lifesciences Corp. | 0.09 | 0.09 | 0.10 | 0.09 | 0.10 | 0.11 | 0.11 | 0.11 | 0.20 | 0.21 | 0.18 | 0.18 | 0.19 | 0.20 | 0.18 | 0.18 | 0.14 | 0.15 | 0.16 | 0.15 | 0.16 | 0.17 | 0.17 | |||||||
Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||
Medtronic PLC | 0.28 | 0.28 | 0.29 | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 | 0.30 | 0.31 | 0.34 | 0.34 | 0.33 | 0.33 | 0.33 | 0.31 | 0.35 | 0.34 | 0.34 | 0.34 | 0.52 | 0.35 | 0.34 | |||||||
Stryker Corp. | 0.41 | 0.41 | 0.36 | 0.37 | 0.32 | 0.32 | 0.33 | 0.36 | 0.33 | 0.33 | 0.36 | 0.33 | 0.34 | 0.35 | 0.35 | 0.34 | 0.34 | 0.37 | 0.38 | 0.25 | 0.22 | 0.21 | 0.21 | |||||||
Thermo Fisher Scientific Inc. | 0.33 | 0.35 | 0.34 | 0.30 | 0.30 | 0.33 | 0.33 | 0.34 | 0.34 | 0.35 | 0.37 | 0.37 | 0.39 | 0.36 | 0.37 | 0.36 | 0.39 | 0.33 | 0.35 | 0.31 | 0.32 | 0.34 | 0.35 | |||||||
UnitedHealth Group Inc. | 0.23 | 0.24 | 0.27 | 0.23 | 0.26 | 0.25 | 0.24 | 0.24 | 0.22 | 0.23 | 0.23 | 0.23 | 0.21 | 0.23 | 0.25 | 0.27 | 0.27 | 0.28 | 0.29 | 0.29 | 0.29 | 0.20 | 0.20 |
Based on: 10-Q (filing date: 2020-10-22), 10-Q (filing date: 2020-07-23), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-21), 10-Q (filing date: 2019-10-24), 10-Q (filing date: 2019-07-18), 10-Q (filing date: 2019-04-18), 10-K (filing date: 2019-02-21), 10-Q (filing date: 2018-10-18), 10-Q (filing date: 2018-07-19), 10-Q (filing date: 2018-04-19), 10-K (filing date: 2018-02-21), 10-Q (filing date: 2017-10-19), 10-Q (filing date: 2017-07-20), 10-Q (filing date: 2017-04-20), 10-K (filing date: 2017-02-22), 10-Q (filing date: 2016-10-20), 10-Q (filing date: 2016-07-25), 10-Q (filing date: 2016-04-21), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-10-22), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-23).
1 Q3 2020 Calculation
Debt to assets = Total debt ÷ Total assets
= 21,825,800 ÷ 72,890,700 = 0.30
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Danaher Corp.’s debt to assets ratio improved from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020. |
Financial Leverage
Danaher Corp., financial leverage calculation (quarterly data)
Oct 2, 2020 | Jul 3, 2020 | Apr 3, 2020 | Dec 31, 2019 | Sep 27, 2019 | Jun 28, 2019 | Mar 29, 2019 | Dec 31, 2018 | Sep 28, 2018 | Jun 29, 2018 | Mar 30, 2018 | Dec 31, 2017 | Sep 29, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jul 1, 2016 | Apr 1, 2016 | Dec 31, 2015 | Oct 2, 2015 | Jul 3, 2015 | Apr 3, 2015 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Total assets | 72,890,700 | 71,268,400 | 68,930,300 | 62,081,600 | 61,531,100 | 53,322,000 | 51,774,400 | 47,832,500 | 47,719,500 | 48,055,800 | 47,145,200 | 46,648,600 | 45,851,300 | 45,646,800 | 45,245,100 | 45,295,300 | 41,297,500 | 51,503,700 | 48,385,600 | 48,222,200 | 49,707,900 | 36,986,800 | 36,072,300 | |||||||
Total Danaher stockholders’ equity | 37,961,000 | 36,261,700 | 31,055,100 | 30,270,600 | 32,502,300 | 32,201,200 | 31,556,600 | 28,214,400 | 27,673,400 | 27,212,300 | 27,189,900 | 26,358,200 | 25,375,400 | 24,590,000 | 23,785,800 | 23,002,800 | 23,191,600 | 25,045,100 | 24,504,700 | 23,690,300 | 23,112,700 | 24,101,200 | 23,321,000 | |||||||
Solvency Ratio | ||||||||||||||||||||||||||||||
Financial leverage1 | 1.92 | 1.97 | 2.22 | 2.05 | 1.89 | 1.66 | 1.64 | 1.70 | 1.72 | 1.77 | 1.73 | 1.77 | 1.81 | 1.86 | 1.90 | 1.97 | 1.78 | 2.06 | 1.97 | 2.04 | 2.15 | 1.53 | 1.55 | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Financial Leverage, Competitors2 | ||||||||||||||||||||||||||||||
Becton, Dickinson & Co. | 2.25 | 2.55 | 2.45 | 2.46 | 2.43 | 2.47 | 2.47 | 2.57 | 2.53 | 2.58 | 2.61 | 2.91 | 2.95 | 3.03 | 3.21 | 3.35 | 3.24 | 3.42 | 3.61 | 3.74 | 3.73 | 3.95 | 3.65 | |||||||
Boston Scientific Corp. | 1.98 | 1.97 | 2.18 | 2.20 | 2.76 | 2.58 | 2.58 | 2.41 | 2.46 | 2.53 | 2.73 | 2.72 | 2.46 | 2.54 | 2.54 | 2.69 | 2.73 | 2.87 | 2.74 | 2.87 | 2.84 | 2.60 | 2.53 | |||||||
Edwards Lifesciences Corp. | 1.62 | 1.67 | 1.56 | 1.56 | 1.56 | 1.59 | 1.59 | 1.70 | 1.77 | 1.80 | 1.79 | 1.93 | 1.74 | 1.75 | 1.74 | 1.72 | 1.61 | 1.64 | 1.68 | 1.62 | 1.60 | 1.58 | 1.58 | |||||||
Intuitive Surgical Inc. | 1.15 | 1.16 | 1.16 | 1.18 | 1.18 | 1.17 | 1.17 | 1.17 | 1.17 | 1.17 | 1.17 | 1.22 | 1.14 | 1.16 | 1.16 | 1.12 | 1.11 | 1.12 | 1.12 | 1.14 | 1.14 | 1.15 | 1.15 | |||||||
Medtronic PLC | 1.79 | 1.80 | 1.81 | 1.79 | 1.78 | 1.78 | 1.79 | 1.80 | 1.91 | 1.84 | 1.98 | 1.98 | 1.98 | 1.96 | 1.94 | 1.92 | 2.02 | 2.01 | 1.98 | 2.00 | 2.74 | 2.00 | 1.95 | |||||||
Stryker Corp. | 2.49 | 2.47 | 2.24 | 2.36 | 2.16 | 2.21 | 2.22 | 2.32 | 2.24 | 2.28 | 2.40 | 2.23 | 2.06 | 2.12 | 2.11 | 2.14 | 2.16 | 2.26 | 2.23 | 1.91 | 1.88 | 1.98 | 1.99 | |||||||
Thermo Fisher Scientific Inc. | 2.01 | 2.06 | 2.05 | 1.97 | 1.93 | 2.02 | 2.01 | 2.04 | 2.05 | 2.10 | 2.17 | 2.23 | 2.27 | 2.08 | 2.12 | 2.13 | 2.22 | 1.99 | 2.05 | 1.92 | 1.97 | 2.02 | 2.10 | |||||||
UnitedHealth Group Inc. | 2.93 | 3.03 | 3.32 | 3.02 | 3.16 | 3.15 | 3.12 | 2.94 | 3.02 | 3.20 | 3.27 | 2.91 | 3.10 | 3.20 | 3.27 | 3.21 | 3.28 | 3.29 | 3.35 | 3.29 | 3.27 | 2.77 | 2.81 |
Based on: 10-Q (filing date: 2020-10-22), 10-Q (filing date: 2020-07-23), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-21), 10-Q (filing date: 2019-10-24), 10-Q (filing date: 2019-07-18), 10-Q (filing date: 2019-04-18), 10-K (filing date: 2019-02-21), 10-Q (filing date: 2018-10-18), 10-Q (filing date: 2018-07-19), 10-Q (filing date: 2018-04-19), 10-K (filing date: 2018-02-21), 10-Q (filing date: 2017-10-19), 10-Q (filing date: 2017-07-20), 10-Q (filing date: 2017-04-20), 10-K (filing date: 2017-02-22), 10-Q (filing date: 2016-10-20), 10-Q (filing date: 2016-07-25), 10-Q (filing date: 2016-04-21), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-10-22), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-23).
1 Q3 2020 Calculation
Financial leverage = Total assets ÷ Total Danaher stockholders’ equity
= 72,890,700 ÷ 37,961,000 = 1.92
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Danaher Corp.’s financial leverage ratio decreased from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020. |
Interest Coverage
Danaher Corp., interest coverage calculation (quarterly data)
Oct 2, 2020 | Jul 3, 2020 | Apr 3, 2020 | Dec 31, 2019 | Sep 27, 2019 | Jun 28, 2019 | Mar 29, 2019 | Dec 31, 2018 | Sep 28, 2018 | Jun 29, 2018 | Mar 30, 2018 | Dec 31, 2017 | Sep 29, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jul 1, 2016 | Apr 1, 2016 | Dec 31, 2015 | Oct 2, 2015 | Jul 3, 2015 | Apr 3, 2015 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Net earnings | 883,500 | 927,300 | 595,100 | 1,275,100 | 668,000 | 731,300 | 333,800 | 746,800 | 663,700 | 673,800 | 566,600 | 856,600 | 572,100 | 557,300 | 506,100 | 747,000 | 391,600 | 656,700 | 758,400 | 688,600 | 1,403,300 | 695,700 | 569,800 | |||||||
Less: Earnings (loss) from discontinued operations, net of income taxes | — | — | — | 482,200 | 37,300 | 54,900 | 1,500 | — | — | — | — | — | — | — | 22,300 | — | (11,000) | 238,700 | 172,600 | (46,600) | 813,300 | (19,800) | 11,800 | |||||||
Add: Income tax expense | 138,000 | 293,600 | 116,000 | 182,600 | 155,900 | 146,800 | 387,700 | 196,500 | 137,600 | 161,300 | 146,500 | 122,400 | 157,700 | 87,500 | 101,400 | (50,600) | 74,100 | 236,600 | 197,800 | 184,500 | 178,500 | 192,200 | 170,100 | |||||||
Add: Interest expense | 76,700 | 78,600 | 47,400 | 44,400 | 24,000 | 19,700 | 20,500 | 33,800 | 41,300 | 43,200 | 39,100 | 41,800 | 39,900 | 40,700 | 40,300 | 32,300 | 43,700 | 55,500 | 52,900 | 59,200 | 45,300 | 29,000 | 29,300 | |||||||
Earnings before interest and tax (EBIT) | 1,098,200 | 1,299,500 | 758,500 | 1,019,900 | 810,600 | 842,900 | 740,500 | 977,100 | 842,600 | 878,300 | 752,200 | 1,020,800 | 769,700 | 685,500 | 625,500 | 728,700 | 520,400 | 710,100 | 836,500 | 978,900 | 813,800 | 936,700 | 757,400 | |||||||
Solvency Ratio | ||||||||||||||||||||||||||||||
Interest coverage1 | 16.90 | 20.00 | 25.33 | 31.44 | 34.40 | 29.52 | 24.77 | 21.92 | 21.12 | 20.86 | 19.99 | 19.06 | 18.34 | 16.31 | 15.04 | 15.16 | 14.42 | 15.68 | 19.13 | 21.42 | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Interest Coverage, Competitors2 | ||||||||||||||||||||||||||||||
Becton, Dickinson & Co. | 2.54 | 2.86 | 2.42 | 2.84 | 3.34 | 3.52 | 3.48 | 2.66 | 2.59 | 1.05 | 1.67 | 2.87 | 2.43 | 4.98 | 4.89 | 3.77 | 4.20 | 3.18 | 2.84 | 2.99 | — | — | — | |||||||
Boston Scientific Corp. | 0.12 | 0.84 | 1.56 | 2.45 | 3.76 | 5.22 | 6.38 | 6.90 | 6.81 | 6.20 | 5.08 | 5.07 | 4.47 | 4.23 | 2.10 | 1.76 | -0.06 | -2.70 | -0.31 | -1.29 | — | — | — | |||||||
Medtronic PLC | 4.12 | 3.84 | 3.76 | 4.60 | 6.40 | 5.94 | 6.14 | 5.95 | 5.81 | 5.77 | 5.34 | 5.21 | 4.35 | 4.49 | 4.24 | 4.13 | 3.81 | 4.08 | 4.82 | 6.23 | — | — | — | |||||||
Thermo Fisher Scientific Inc. | 10.78 | 7.93 | 7.66 | 7.02 | 8.57 | 11.90 | 19.23 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
UnitedHealth Group Inc. | 14.12 | 13.89 | 11.40 | 11.55 | 11.63 | 12.08 | 12.32 | 12.39 | 12.61 | 12.80 | 12.86 | 12.82 | 12.58 | 12.41 | 12.27 | 12.12 | 11.53 | 11.43 | 12.62 | 13.95 | — | — | — |
Based on: 10-Q (filing date: 2020-10-22), 10-Q (filing date: 2020-07-23), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-21), 10-Q (filing date: 2019-10-24), 10-Q (filing date: 2019-07-18), 10-Q (filing date: 2019-04-18), 10-K (filing date: 2019-02-21), 10-Q (filing date: 2018-10-18), 10-Q (filing date: 2018-07-19), 10-Q (filing date: 2018-04-19), 10-K (filing date: 2018-02-21), 10-Q (filing date: 2017-10-19), 10-Q (filing date: 2017-07-20), 10-Q (filing date: 2017-04-20), 10-K (filing date: 2017-02-22), 10-Q (filing date: 2016-10-20), 10-Q (filing date: 2016-07-25), 10-Q (filing date: 2016-04-21), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-10-22), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-23).
1 Q3 2020 Calculation
Interest coverage
= (EBITQ3 2020
+ EBITQ2 2020
+ EBITQ1 2020
+ EBITQ4 2019)
÷ (Interest expenseQ3 2020
+ Interest expenseQ2 2020
+ Interest expenseQ1 2020
+ Interest expenseQ4 2019)
= (1,098,200 + 1,299,500 + 758,500 + 1,019,900)
÷ (76,700 + 78,600 + 47,400 + 44,400)
= 16.90
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Danaher Corp.’s interest coverage ratio deteriorated from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020. |